The partnership combines AI-powered evidence synthesis and scientific communications to help pharmaceutical teams move from information overload to actionable insights.
Life sciences organizations have never had more data at their fingertips. Between scientific publications, clinical trial updates, competitor announcements, and medical congress presentations, teams are inundated with information. The challenge is no longer finding evidence it is transforming that evidence into decisions.
That challenge is precisely what Prezent Vivo and Nested Knowledge aim to solve through a newly announced strategic partnership that combines automated evidence synthesis with AI-powered scientific communications.
The collaboration brings together Prezent Vivo, known for its AI-powered business communication platform for life sciences enterprises, and Nested Knowledge, whose evidence synthesis technology helps researchers conduct systematic literature reviews in a fraction of the traditional time. Together, the companies are creating an integrated intelligence solution designed for pharmaceutical and biotechnology organizations navigating increasingly complex competitive environments.
At the core of the partnership is the integration of Nested Knowledge’s AutoLit synthesis engine with Prezent Vivo’s AI-plus-human expertise model. AutoLit can complete rapid literature reviews in less than 30 minutes and reduce systematic review timelines by more than 70%, while Prezent Vivo transforms those findings into polished, audience-ready communications tailored to specific business needs.
The result is a workflow that enables teams to receive congress-ready competitive intelligence packages before major medical meetings begin, while also maintaining continuous visibility into emerging evidence throughout the year.
According to the companies, the partnership addresses a longstanding operational problem in life sciences organizations. While valuable evidence and competitive insights are widely available, they are often scattered across multiple sources and presented in formats that are difficult for medical affairs, commercial, and market access teams to operationalize quickly.
Rajat Mishra, CEO and Co-Founder of Prezent, said the collaboration reflects a broader shift in how life sciences organizations are approaching intelligence and decision-making.
“At Prezent Vivo, we believe extraordinary impact comes from fusing AI speed with human expertise,” Mishra said. “This partnership helps life sciences teams move from evidence to action faster than ever before.”
Francine Carrick, President of Prezent Vivo, said the idea for the partnership emerged from conversations about the growing gap between available intelligence and teams’ ability to use it effectively.
“Keith and I were talking about how much intelligence exists in life sciences, and how hard it is for field-facing teams to actually use it when it matters,” Carrick said. “We both saw immediately that we could do something really special here—reaching more teams, more quickly, with insights that speak directly to their individual challenges.”
The companies will jointly offer several services, including congress intelligence packages, monthly living evidence updates, rapid-response deep dives on emerging competitive developments, and customized deliverables tailored to specific therapeutic areas and stakeholder groups.
The timing of the launch is notable. The partnership debuts during one of the busiest periods on the medical congress calendar, with events such as ASCO, EHA, and ISTH expected to generate significant volumes of new clinical data. Participating organizations will receive pre-congress briefings as well as post-presentation synthesis packages designed to translate newly released findings into practical implications for decision-makers.
Keith Kallmes, President of Nested Knowledge, believes the collaboration fills a critical gap between evidence generation and organizational action.
“Prezent Vivo’s AI + human expertise model is exactly the delivery layer that evidence synthesis has been missing,” Kallmes said. “What’s been missing is the translation layer that turns that synthesis into action.”
Beyond congress season, the companies see broader implications for the future of life sciences operations. As organizations increasingly seek to streamline workflows and reduce reliance on fragmented vendor ecosystems, integrated AI-powered solutions are becoming more attractive.
